Isogenica develops highly versatile, small-format VHH antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation, and other serious diseases.  

VHH can be assembled to create multi-specific biotherapeutics or used to achieve targeted drug delivery as components of ADCs and cell therapies including CAR-Ts.  

We are leaders in antibody discovery and engineering. Drawing on our 20 years of expertise and knowledge, we have built a unique and proven engine for biotherapeutic development and our own deep pipeline including two clinical stage assets.